Publicação científica trimestral do CREMERJ - número 4 - 2022

85 Med. Ciên. e Arte , Rio de Janeiro, v.1, n.4, p.74-85, out-dez 2022 Microbioma e doença pulmonar obstrutiva crônica Hisbello da Silva Campos 55. Yamamoto M, Tochino Y, Chibana K, Trudeau JB, Holguin F, Wenzel SE. Nitric oxide and related enzymes in asthma: relation to severity, enzyme function and inflammation. Clin Exp Allergy. 2012;42(5):760-8. 56. Kanazawa H, Yoshikawa J. Elevated oxidative stress and reciprocal reduction of vascular endothelial growth factor levels with severity of COPD. Chest. 2005;128(5):3191-7. 57. Vogelmeier CF, Román-Rodríguez M, Singh D et cols. Goals of COPD treatment: Focus on symptoms and exacerbations. Respir Med 2020;166:105938. 58. Celli BR, Singh D, Vogelmeier C et col. New Perspectives on Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis 2022;17:2127-2136. 59. Bhatt SP, Blauer-Peterson C, Buysman EK et cols. Trends and Characteristics of Global Initiative for Chronic Obstructive Lung Disease Guidelines-Discordant Prescribing of Triple Therapy Among Patients with COPD. Chronic Obstr Pulm Dis 2022;9(2):135-153. 60. Miravitlles M, Auladell-Rispau A, Monteagudo M, et cols. Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD. Eur Respir Ver 2021;30(160):210075. 61. Yagi K, Huffnagle GB, Lukacs NW et col. The lung microbiome during health and disese. Int J Mol Sci 2021;22:10872.